Eli Lilly to buy Orna Therapeutics for $2.4 billion. Orna Therapeutics focuses on the development of "in vivo" CAR-T therapies for the treatment of autoimmune diseases. This is the acquisition of a biotechnology company specializing in innovative cell therapies directly in the patient's body. The transaction strengthens Eli Lilly's immunology portfolio. Details on the structure of the agreement or milestones are not provided in the article. The acquisition is part of Lilly's strategy to expand its immunotherapy programs.